Retina BioBank: Retina Biomarkers for a Deeper Understanding of Vitreoretinal and Systemic Diseases
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- Enrollment
- 10,000
- Locations
- 1
- Primary Endpoint
- To quantify levels of disease state biomarkers implicated in the pathogenesis of various retinal and systemic pathologies
Study Overview
Brief Summary
The RBBK study is a non-interventional, prospective study that will characterize disease state biomarker levels from aqueous humor, vitreous humor, intraoperative tissue and saliva of subjects with various retinal and systemic pathologies.
Detailed Description
The RBBK study is a non-interventional, prospective study that will characterize disease state biomarker levels from aqueous humor, vitreous humor, intraoperative tissue and saliva of subjects with various retinal and systemic pathologies.
Participants are eligible to be included in the study only if all of the following criteria apply:
- Men or women > 18 years of age
- Subjects with vitreoretinal disease in at least one eye receiving a retinal treatment intervention
- Able and willing to provide signed informed consent
The study will consist of a single visit and a retrospective chart review. The study visit will consist of:
- Screening for eligibility;
- Aqueous humor collection (if applicable);
- Vitreous humor collection (if applicable);
- Intraoperative tissue (if applicable); and
- Saliva collection
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects with vitreoretinal disease in at least one eye receiving a retinal treatment intervention
Exclusion Criteria
- •Prior intraocular or subtenon steroid injection in the study eye within the prior 1 month of signing informed consent
- •Intraocular or refractive surgery in the study eye within 30 days of signing informed consent
- •Systemic anti-VEGF treatment within 90 days of signing informed consent
Outcomes
Primary Outcomes
To quantify levels of disease state biomarkers implicated in the pathogenesis of various retinal and systemic pathologies
Time Frame: Baseline
An analysis of the ocular fluids and tissues of patients with various vitreoretinal diseases would allow for the development of a deeper understanding of the processes that contribute to their onset and may ultimately provide insight in methods to refine treatment and management options.
Secondary Outcomes
No secondary outcomes reported